Tanespimycin (17-AAG) Liposomes, Formulation XT28.1

Catalog #	Pkg Size	Price(USD)	Quantity	Buy this product
R-R-5666	2mL	985.00	- +	+ Add to cart
R-R-5666	10ml	2985.00	- +	+ Add to cart

Product description

Tanespimycin (17-AAG) Liposomes, Formulation XT28.1. PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Appearance	N/A
Concentration, Total Lipid	60 mM
Hydration Solution	300 mM sucrose
External Solutio	300 mM sucrose
Average Size	70-120 nm
Storage	2 °C to 8 °C (do not freeze), protect from light
Transportation	4-25℃ temperature for up to 2 weeks
Stability	6 months

Document